Innovative Approaches in Cancer Trials in Ireland: Evaluating the Effectiveness and Challenges of Complex Innovative Design (CID)

dc.contributor.authorSchneider da Rosa, Kerrollyn
dc.date.accessioned2024-10-29T15:13:13Z
dc.date.available2024-10-29T15:13:13Z
dc.date.issued2024
dc.description.abstractThis study investigated Complex Innovative Design (CID) trials in cancer research through a detailed survey of professionals including researchers, clinicians, and industry experts. The survey combined qualitative and quantitative questions to provide a broad perspective on CID trials' effectiveness, the challenges encountered, and the impact on patient outcomes. The results revealed that CID trials are generally seen as beneficial in accelerating drug development, with 55.2% of respondents finding them either extremely or very effective. Despite these positive perceptions, the survey highlighted significant challenges such as data management, coordination among stakeholders, and compliance with regulatory standards. Qualitative feedback identified specific issues like the complexity of trial design and regulatory hurdles. The study also examined how CID trials influence patient outcomes, noting advancements in personalized treatment but underscoring the necessity for stringent safety monitoring. By integrating both types of data, the study offered a comprehensive view of CID trials and proposed recommendations to refine trial methodologies and regulatory frameworks, aiming to enhance future cancer research and drug development efforts
dc.identifier.urihttps://hdl.handle.net/20.500.14136/192
dc.titleInnovative Approaches in Cancer Trials in Ireland: Evaluating the Effectiveness and Challenges of Complex Innovative Design (CID)
dc.typeThesis
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
_Kerollyn_Schneider_Da_Rosa.pdf
Size:
4.56 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.69 KB
Format:
Item-specific license agreed to upon submission
Description: